Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25872146 | 0.80 | MAPT (0.47) | MAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL15932486 | 0.77 | BRD4 (0.49) | — | |
| SCHEMBL23547627 | 0.72 | ATM (0.41) | POLBL3MBTL1KMT2A | |
| SCHEMBL25023347 | 0.72 | ATM (0.41) | POLBL3MBTL1KMT2A | |
| SCHEMBL25227301 | 0.71 | MAPT (1.00) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL2164818 | 0.71 | MAPT (1.00) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL25209200 | 0.71 | MAPT (1.00) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL11622652 | 0.70 | MAPT (0.66) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL12667143 | 0.70 | MAPT (0.66) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL21827346 | 0.70 | MAPT (0.60) | MAPTLMNAPOLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | MAPT 4192/4885LMNA 3441/4885POLB 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.